These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 2893743)

  • 1. [Liquid chromatography in pharmaceutical analysis: determination in tablets of famotidine, a new H2-antagonists].
    Ficarra R; Ficarra P; Calabrò ML
    Farmaco Prat; 1987 Nov; 42(11):307-12. PubMed ID: 2893743
    [No Abstract]   [Full Text] [Related]  

  • 2. Analytical method for the quantification of famotidine, an H2-receptor blocker, in plasma and urine.
    Vincek WC; Constanzer ML; Hessey GA; Bayne WF
    J Chromatogr; 1985 Mar; 338(2):438-43. PubMed ID: 2860117
    [No Abstract]   [Full Text] [Related]  

  • 3. Visual compatibility of intravenous famotidine with selected drugs.
    Fong PA; Ward J
    Am J Hosp Pharm; 1989 Jan; 46(1):125-6. PubMed ID: 2565686
    [No Abstract]   [Full Text] [Related]  

  • 4. Application of ninhydrin to spectrophotometric determination of famotidine in drug formulations.
    Rahman N; Kashif M
    Farmaco; 2003 Oct; 58(10):1045-50. PubMed ID: 14505737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of plasma, urine and gastric juice concentrations of famotidine using high performance liquid chromatography.
    Bologna M; Biordi L; Napolitano T; Carlucci G
    Int J Clin Pharmacol Res; 1988; 8(5):335-40. PubMed ID: 3229873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-performance liquid chromatographic assay for nizatidine, a new H2 blocker, in human plasma and urine using disposable solid-phase extraction columns.
    Carlucci G
    J Chromatogr; 1990 Feb; 525(2):490-4. PubMed ID: 1970345
    [No Abstract]   [Full Text] [Related]  

  • 7. [Turbidimetric assay of famotidine].
    Apostu M; Dorneanu V; Bibire N; Vieriu M
    Rev Med Chir Soc Med Nat Iasi; 2006; 110(2):460-4. PubMed ID: 17802962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potentiometric determination of famotidine in pharmaceutical formulations.
    Ayad MM; Shalaby A; Abdellatef HE; Elsaid HM
    J Pharm Biomed Anal; 2002 Jun; 29(1-2):247-54. PubMed ID: 12062684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HPLC reveals famotidine in the urine up to five days after a single 20 mg oral dose.
    Bologna M; Napolitano T; Biordi L; Carlucci G
    Drugs Exp Clin Res; 1988; 14(6):419-21. PubMed ID: 2905638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-performance liquid chromatographic determination of famotidine in urine.
    Rahman A; Hoffman NE
    J Chromatogr; 1988 Jul; 428(2):395-401. PubMed ID: 2905703
    [No Abstract]   [Full Text] [Related]  

  • 11. [High pressure liquid-liquid chromatography. Quantitative determination of histamine H2 antagonists].
    Gaetani E; Laureri CF; Ronchini F
    Farmaco Prat; 1978 Nov; 33(11):484-8. PubMed ID: 35364
    [No Abstract]   [Full Text] [Related]  

  • 12. Optimization and validation of a dissolution test for famotidine tablets using flow injection analysis.
    Tzanavaras PD; Verdoukas A; Balloma T
    J Pharm Biomed Anal; 2006 May; 41(2):437-41. PubMed ID: 16413732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous determination of cimetidine, famotidine, nizatidine, and ranitidine in tablets by capillary zone electrophoresis.
    Wu SM; Ho YH; Wu HL; Chen SH; Ko HS
    Electrophoresis; 2001 Aug; 22(13):2758-62. PubMed ID: 11545404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of the stability of polymeric matrix tablets containing famotidine from the positron annihilation lifetime distributions of their physical mixtures.
    Szente V; Süvegh K; Marek T; Zelkó R
    J Pharm Biomed Anal; 2009 Apr; 49(3):711-4. PubMed ID: 19188038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetic spectrophotometric determination of famotidine in commercial dosage forms.
    Rahman N; Kashif M
    Anal Sci; 2003 Jun; 19(6):907-11. PubMed ID: 12834233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [UV spectrophotometric assay of famotidine in combination with picrolonic acid, picrolinate].
    Apostu M; Bibire N; Dorneanu V
    Rev Med Chir Soc Med Nat Iasi; 2005; 109(2):422-5. PubMed ID: 16607813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The antisecretory profile of action of the H2-receptor antagonists, famotidine, loxtidine, ranitidine and L-643,441 on the rat isolated gastric mucosa.
    Reeves JJ; Stables R
    Agents Actions; 1987 Feb; 20(1-2):22-8. PubMed ID: 2883848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extractional-spectrophotometric determination of famotidine in pharmaceutical formulations.
    Abu Zuhri AZ; Shubietah RM; Badah GM
    J Pharm Biomed Anal; 1999 Nov; 21(2):459-65. PubMed ID: 10704003
    [No Abstract]   [Full Text] [Related]  

  • 19. Spectrofluorimetric analysis of famotidine in pharmaceutical preparations and biological fluids by derivatization with benzoin.
    Alamgir M; Khuhawar MY; Memon SQ; Hayat A; Zounr RA
    Spectrochim Acta A Mol Biomol Spectrosc; 2015 Jan; 134():449-52. PubMed ID: 25033237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversed-phase determination of famotidine, potential degradates, and preservatives in pharmaceutical formulations by high-performance liquid chromatography using silica as a stationary phase.
    Biffar SE; Mazzo DJ
    J Chromatogr; 1986 Aug; 363(2):243-9. PubMed ID: 3771687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.